Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters  by Bassleer, Corinne T. et al.
Osteoarthritis and Cartilage (1996) 4, 1-8 
© 1996 Osteoarthritis Research Society 1063-4584/96/010000 + 8$12.00/0 
OSTEOARTHRITIS 
and 
CARTILAGE 
Effects of Ipriflavone and its metabol i tes on human art icular 
chondrocytes cult ivated in c lusters 
BY CORINNE T. BASSLEER*, PAUL P. FRANCHIMONT*, YVES E. HENROTIN*, NATHALIE M. FRANCHIMONT*, 
VINCENT G. GEENEN* AND JEAN-YVES L. REGINSTERt, ~: 
*Department of Endocrinology, B23, Radioimmunoassay Laboratory, University Hospital-Sart- Tilman, 
Liege, Belgium," tCenter for Bone and Articular Cartilage Research, University Hospital Centre Ville, 
University of Liege, Liege, Belgium," ~-Georgetown U iversity Medical Center, Washington D.C., U.S.A. 
Summary  
Ipriflavone (IP) is an isoflavone derivative that was suggested to have bone-sparing effects in post-menopausal and senile 
osteoporosis. A moderate stimulatory effect of IP and its metabolites on proliferation of osteoblastic cells was reported 
in rat osteoblastic osteosarcoma cell line. We investigated the effects of different concentrations (0,1, 10 and 100 pg/ml) 
of IP and its metabolites (MET I, II, III and V) on the incorporation of [3H]thymidine and production of proteoglycans 
(PG) and type II collagen (COL II) by human articular chondrocytes during a 12-day period, in a three-dimensional 
chondrocyte culture model. [3H]thymidine uptake was measured in chondrocyte clusters, and specific PG and COL II 
radioimmunoassays were performed every 4 days on the culture medium and cell clusters. Incubation with IP or its 
metabolites did not affect [3H]thymidine uptake regardless of the dose. PG released into the culture medium and PG 
cluster content rose significantly (P < 0.025) in presence of IP (1, 10 and 100 #g/ml). MET I increased PG release in 
culture medium (10 and 100 #g/ml) and PG cluster content (100/lg/ml). MET II has no effect on PG production. MET 
III increased PG in culture medium (100 #g/ml) but did not influence PG cluster content while MET V (100 #g/ml) 
increased both PG release in culture medium and PG cluster content. COL II release in culture medium and COL II 
cluster content were significantly (P < 0.025) increased in presence of IP (10 and 100 pg/ml), MET III (1, 10 and 
100 pg/ml) or MET V (100 #g/ml). MET I and II did not significantly affect COL II production. 
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Introduct ion 
IPRIFLAVONE (IP) is an isoflavone derivative 
available in several countr ies  for investigational 
andJor therapeut ic  use. This substance was shown 
to have bone-sparing effects in post-menopausal  
and senile osteoporosis [1-3]. IP appears to act 
predominant ly  as an inhib i tor  of bone resorpt ion 
[4] but a moderate st imulatory effect on prolifer- 
at ion of osteoblast ic cells was reported in rat 
osteoblastic oste0sarcoma cell l ine [5] and in 
stromal cells from the  femoral  bone marrow of 
young adult  rats [6]. We have shown previously that 
calcitonin, another  substance predominant ly  in- 
hibit ing osteoclast ic resorpt ion [7], but also 
suggested to increase osteoblast prol i ferat ion and 
di f ferent iat ion at pharmacologica l  doses [8, 9], may 
possess chondroprotect ive propert ies in addit ion 
to its other  known effects [10]. Therefore, we 
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investigated the effects of IP and its main 
metabol ites [11] on the chondroformative processes, 
cell prol i ferat ion and matr ix  formation, of human 
art icu lar  chondrocytes cult ivated in three dimen- 
sions [12]. 
Dissociated chondrocytes form a cluster after a 
prol i ferative phase in this model. Morphologica l ly  
differentiated, these chondrocytes are s i tuated 
inside cavities and surrounded by a newly 
synthesized matr ix  composed of type II col lagen 
(COL II) and cart i lage proteoglycons (PG). The 
purpose of this investigation was to determine the 
effects of IP and its metabol i tes on cell multipl i-  
cat ion and COL II and PG synthesis by human 
chondrocytes in three-dimensional  culture. 
Materials and Methods 
HUMAN CHONDROCYTES IN CULTURE 
The technique used has been described in detail  
[12]. Briefly, human carbonate-b icarbonate buffer 
(120 mmol/1 NaC1, i mmol/1 CaC12, 5 mmol/1 KC1, 
lmmol /1 KH2PO4, 25mmol/1 NaHCO3, 2mmol/1 
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glucose and 30 mmol/1 HEPES, pH 7.4) during 24 h. 
After six successive washings and centrifugations, 
cells were suspended in flasks (106 cells per 2 ml 
culture raedium) placed on a gyratory shaker 
(100 r.p.m.), with cultures maintained at 37°C in a 
95% air-5% CO2 humidified atmosphere. Upon 
cultivation, human chondrocytes were incubated 
with 0, 1, 10 or 100 #g/ml (0, 4, 40 and 400 #M) of IP 
or its metabolites (MET I, II, III, and V) (Chiesi, 
Parma, Italy). Culture media were collected and 
renewed every 4 days for 12 days and were 
refrigerated for subsequent radioimmunoassay 
(RIA) determinations of COL II and PG. These 
parameters were also measured directly in the 
chondrocytes clusters. Four flasks were used for 
each IP and its metabolites test concentration and 
corresponding control. The assays were run four 
times for each compound at each concentration 
tested. We used chondrocytes from the femoral 
head of a single patient. 
PG R IA  
PG released into culture medium and present 
inside chondrocyte clusters were assayed as 
described previously [13]. Briefly, human cartilage 
PG were extracted according to the methods of 
Roughley et al. [14] and Bayliss and Venn [15]. 
Antiserum against human cartilage PG was raised 
in rabbits according to the method of Vaitukaitis 
et al. [16]. Antibodies are directed against he core 
protein of human cartilage PG. No cross-reactivity 
was observed with glycosaminoglycans ( uch as 
chondroitin sulfate or keratan sulfate) nor with PG 
treated with various enzymes. 
The RIA was performed in a 0.4 ml incubation 
volume consisting of 0.1 ml tracer solution (15 000- 
20000 cpm ~25I-labeled PG by the chloramine-T 
method [17], 0.1ml anti-PG antiserum diluted 
1:5000 in a phosphate-buffered saline (PBS, 
0.15 mmol/1 NaC1) containing 5 g/1 bovine serum 
albumen (BSA, incubation buffer), and 0.2ml 
of several dilutions of conditioned culture 
medium, chondrocyte cluster extract, or the 
unlabeled antigen ranging from 0.1-500ng per 
tube (reference curve). After 4 days at 4°C, the 
labeled PG-antibody complexes were separated by 
double precipitation [18]. The analytical sensitivity 
of the RIA was 0.6rig per tube. The intra- and 
interassay coefficients of variation were < 10 and 
20%, respectively, along the linear part of the 
curve. 
As proven by digestion experiments and the 
absence of cross-reactivity with glycosaminogly- 
cans, the antibodies are directed solely against he 
antigenic determinants of the PG protein core. In 
addition, there were complete cross-reactions 
with human costal, vertebral disk and tracheal 
cartilage PG while the PG extracted from vein 
and artery did not significantly interfere in our 
assay. No cross-reactivity was found with PG 
extracted from various fetal tissues and small PG 
from bone. However, large PG from bone produced 
a weak cross-reaction, amounting to an 800-fold 
diminution in immunoreactivity compared with 
cartilage PG at 10% displacement. Furthermore, 
the assay was species specific, since cartilage 
from dog, rat, chicken and calf embryos either 
did not cross-react or cross-reacted weakly in 
the assay. COL II, fibronectin, chondroitin sulfate 
and hyaluronic acid did not interfere with the 
assay. 
Culture media were assayed directly for PG. 
Chondrocyte clusters were washed three times 
with PBS, then homogenized in PBS by ultrasonic 
dissociation for I min at 4°C (power:200W/cm2). 
Extraction permitted recovery of 70-80% of all 
HCl-guanidine extractable PG. 
COL I I  R IA  
COL II, assayed radioimmunologically according 
to the method of Henrotin et al. [19], was extracted 
from human articular cartilage base on the method 
of Herbage et al. [20] and used as immunogen, 
tracer and reference preparation. The RIA was 
performed in a 0.4 ml solution containing 0.1 ml 
'25I-labeled COL II using the iodogen R method [21] 
and diluted to obtain 20 000 cpm; 0.1 ml incubation 
buffer (PBS:0.3mol/1 NaC1); 0.1ml of COL II 
reference solution (1-500 ng), culture medium, or 
cluster extracts; and 0.1 ml guinea-pig antiserum 
diluted 1:5000. After a 4 h incubation at 4°C, the 
collagen-antibody complexes were separated from 
freely labeled collagen by the double antibody 
system [18]. Cartilage PG, fibronectin, laminin, 
link protein as well as type I, II, VI and IX 
collagen did not cross-react with COL II in the 
RIA. The detection limit for the assay was 5 ng per 
tube. The intra-assay coefficient of variation 
ranged from 5-10% for amounts of unlabeled 
COL II ranging from 10-200 ng per tube. The 
interassay coefficient of variation of COL II 
concentration measurements ranged from 5-12% 
for amounts of unlabeled COL II ranging from 
10-200 ng per tube. These values are within the 
same range as those published by Srinivas and 
colleagues [22], who reported a precision of 5% and 
a reproducibil ity of 9.3%, considering only the 
central part of the reference curve of the 
quantitative immunoassay [enzyme-linked immuno- 
sorbent assay (ELISA)]. 
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Culture media were assayed irectly for COL II. 
Chondrocyte clusters were washed three times 
with PBS, then homogenized in PBS by ul trasonic 
dissociat ion for 2 x 30 s at 4°C (power:200 W/cm2). 
After centr i fugation, the residue was extracted 
with 0.5 ml, 0.5 mol/1 acetic acid for 24 h at 4°C 
under  gentle agitation. The supernatant  of the 
homogenate and extract of the residue were mixed 
and assayed by the above-described procedure after 
equi l ibrat ion at pH 7.5 with incubat ion buffer. 
Recovery of COL II was 88 + 8% (mean_+ S.D.) 
compared with that  using the method of Herbage 
et al. [20]. 
ANALYSIS OF CELL MULTIPLICATION 
After different culture durat ions in the presence 
of IP and its metabol ites (3, 7 or 11 days), 
chondrocyte clusters were incubated further  in 
culture medium contain ing IP or its metabol ites 
and 2ttCi/ml (5Ci/mmol) methyl-[3H]thymidine 
(Amersham, Brussels, Belgium) for 24h. After 
incubation, chondrocyte clusters were washed 
with PBS and ultrasonicated. Incorporated radio- 
activity was measured with a fl-counter, and 
chondrocyte DNA content  was assessed according 
to the f luorimetric method of Labarca and Paigen 
[23]. 
STATISTICAL ANALYSIS 
Results were expressed as rates of release 
in culture medium per 96h and per pg DNA 
(production release into culture medium) and as 
amounts found in chondrocyte cluster per 96 h 
and per ]~g DNA (content inside clusters). The 
mean _ S.D. of [3H]thymidine incorporation and 
COL II and PG release and content were calculated 
for each concentration. Comparison of mean 
values was performed using the Mann-Whitney 
U-test at each period of incubation. Differences 
were considered statist ical ly signif icant when 
P < 0.025. 
Resu l ts  
EFFECTS OF IP AND ITS METABOLITES ON 
[3H]THYMIDINE INCORPORATION 
Incorporat ion of [3H]thymidine into the DNA 
of controls increased dur ing the first days of 
culture, reaching a maximum after 8 days, then 
decreasing as a funct ion of culture durat ion. 
Incubat ion with different doses of IP  and 
its metabol ites for 4, 8 or 12 days did not 
affect [3H]thymidine incorporat ion into DNA 
(Table I). 
Table I. 
[SH]thymidine incorporation into DNA (percent of controls) of human 
chondrocytes cultured in clusters in the presence of Ipriflavone and its 
metabolites 
Culture 
duration (days) Controls 1 #g/ml 10 #/ml 100 #g/ml 
Ipriflavone 
0-4 100 _+ 16.5 92 _+ 17.5 107 _+ 13.2 89 _+ 17.8 
4-8 100 + 14.9 109 +_ 11.2 104 _+ 13.8 99 _+ 9.1 
8-12 100 _+ 16.1 105 _+ 17.8 101 _+ 15.3 93 _+ 18.1 
MET I 
0-4 100 +_ 16.6 106 +_ 21.6 103 _+ 13.6 97 _+ 14.6 
4-8 100 _+ 16 102 _ 10.1 103 _+ 8.7 99 _+ 10.4 
8-12 100 _+ 15.1 104 _+ 11.9 102 + 12.2 101 _+ 18.7 
MET II 
0-4 100 _+ 14.7 107 _+ 15.3 106 +_ 12.4 99 +__ 11.2 
4-8 100 _+ 12.2 101 _+ 12.6 102 +_ 12.6 101 _+ 10.2 
8-12 100 _+ 12.1 106 _+ 18.3 105 Jr 10.8 105 + 12.5 
MET III 
0-4 100 _ 16.7 110 _ 19 102 +_ 13.7 99 _+ 16.7 
4-8 100 _+ 11.1 101 +_ 11.2 102 _+ 10.1 99 _+ 7.5 
8-12 100 _+ 11.9 106 _+ 18.3 105 _+ 8.9 102 _+ 14.3 
MET V 
0-4 100 _+ 14.1 101 + 8.8 103 _+ 9.8 100 _+ 8.6 
4-8 100 +_ 12.2 101 _+ 12.2 101 _+ 11.1 100 _+ 12.2 
8-12 100 + 15.6 106 ± 13.6 98 _+ 16.1 100 _+ 13.3 
Values are the mean ± S.D. There were no significant intergroup differences for any 
culture duration. MET, metabolite. 
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Table II. 
Cartilage proteoglycans (percent of controls) released into culture medium as a 
function of culture duration and dose of Ipriflavone and its metabolites 
Culture 
duration (days) Controls 1 #g/ml 10 #g/ml 100 pg/ml 
Ipriflavone 
0-4 100 ± 6.5 129 + 15.7" 129 ± 18.6" 122 ± 18.6" 
4-8 100 ± 10.5 120 ± 17.4" 130 ± 26.7* 134 ± 15.7" 
8-12 100 ± 20.8 121 ± 10.4" 139 + 14.6" 135 ± 18.7" 
MET I 
0-4 100 ± 18.6 106 ± 14.7 114 ± 14.4 121 ± 10" 
4-8 100 ± 18.7 100 ± 19.7 129 ± 21.1" 144 ± 22.1" 
8-12 100 ± 15.3 100 ± 23.1 139 ± 13.1" 154 ± 31.5" 
MET II 
0-4 100 ± 16 117 ± 20 106 ± 18 112 ± 21.1 
4-8 100 ± 19.1 98 ± 16.7 93 ± 14.3 93 ± 16.7 
8-12 100 ± 14.3 105 ± 19 105 ± 14.3 105 ± 14.3 
MET III 
0-4 100 ± 13.8 104 ± 16 99 ± 10.2 139 ± 26.3* 
4-8 100 ± 14.9 104 ± 17.6 97 ± 10.8 124 ± 17.6" 
8-12 100 ± 14.3 112 ± 21.4 100 ± 1.43 124 ± 19" 
MET V 
0-4 100 ± 11.1 105 ± 13.5 111 ± 17.1 142 ± 18.6" 
4-8 100 ± 11.7 108 ± 19.8 109 ± 18.1 126 ± 10.1" 
8-12 100 ± 9.6 95 ± 4.9 107 ± 13.7 124 ± 7.8* 
Stat i s t i ca l  s ignif icance: *P < 0.025 vs controls.  MET, metabol i te.  
EFFECTS OF IP AND ITS METABOLITES ON PG AND 
COL II  SYNTHESIS 
In the absence or presence of IP and its 
metabolites, PG and COL II synthesis reached 
a maximum during the first days of culture, 
then progressively decreased as a funct ion of 
culture duration. PG released into the cul ture 
medium (Table II) and PG cluster content  
(Fig. 1) rose signif icantly (P < 0.025) in presence 
of IP (1, 10 and 100pg/ml). MET I increased 
PG release in cul ture medium (10 and 100 pg/ml) 
and PG cluster content  (100 #g/ml). MET II has 
no effect on PG product ion.  MET III increased 
PG in cul ture medium (100 pg/ml) but did not 
inf luence PG cluster content  while MET V 
(100 gg/ml) increased both PG release in cul ture 
medium and cluster content.  The effect of IP 
and MET I, III and V on PG synthesis was 
present dur ing each per iod of incubat ion (0-4, 4-8 
and 8-12 days), except for MET I effect on PG 
release in cul ture medium, which was only 
present during the 4-8 and 8-12 days periods of 
incubation. 
COL II release in cu l ture  medium and COL II 
cluster content  (Fig. 2) were signif icantly 
(P < 0.025) increased in presence of IP (10 and 
100 #g/ml), MET III (1, 10 and 100 #g/ml) and MET 
V (100 #g/ml). MET I and II did not signif icantly 
affect COL II product ion.  
Discuss ion  
The abil ity of human chondrocytes to differen- 
t iate morphological ly  and b iosynthet ica l ly  in 
three-dimensional  cu l ture offers a useful model for 
the study of two aspects of chondroformation:  cell 
prol i ferat ion and matr ix  product ion [12]. Previous 
observat ions in such cultures [12] indicated that 
maximum [3H]thymidine uptake by human chon- 
drocytes occurred on days 8-9 of culture, when 
radioact iv i ty  was located both inside and at the 
borders of chondrocyte clusters; [~H]thymidine 
incorporat ion subsequent ly diminished, and auto- 
h istoradiography showed that  rad ioact iv i ty  was 
chiefly located in the cells border ing the aggregates 
on days 16 and 20 of incubation.  The present data 
on [SH]thymidine incorporat ion agreed with these 
earl ier results. Moreover, optic microscope obser- 
vations showed that, even in long-term cul ture ( > 1 
month) cells are kept in excel lent conditions. 
Similarly, Weiss et al. [24] have shown that  the 
progenitor  zone of the newborn  mouse condylar  
carti lage, if cu l tured as an intact  explant, can 
mainta in its capacity for cell prol i ferat ion with 
subsequent chondrogenic di f ferent iat ion of the 
daughter  cell. This prol i ferative activity tends to 
decrease as a funct ion of cul ture durat ion,  with the 
surrounding matr ix  seemingly involved in the 
regulat ion of chondrocyte repl icat ion in vivo and 
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FIG. 3. Chemical structure of Ipriflavone (IP) and its main metabolites (MET) and postulated metabolic pathways. 
in vitro. Furthermore, various collagens found in 
cartilage (types II, VI and X) as well as PG are 
involved in maintaining the chondrocyte with a 
chondrogenic phenotype, but can possibly also 
support and enhance cartilage repair [25]. More- 
over, COL I and III were assayed by ELISA in 
clusters and in conditioned culture media and were 
not detectable, demonstrating the differentiated 
stage of the chondrocytes. 
Bioflavonoids are benzo-gamma-pyrone deriva- 
tives found in most photosynthesizing cells. They 
show a wide range of pharmacological properties, 
the mechanisms of which remain to be fully 
elucidated [25]. Flavonoids were shown to be potent 
inhibitors of several enzymes, including 5-1ipoxyge- 
nase and cyclo-oxygenase [26, 27], cAMP phospho- 
diesterase [28], hyaluronidase [29], tyrosine 
protein kinase [30], DNA topoisomerases I and II 
[31], viral reverse transcriptase [32] and protein 
kinase [33]. They were reported to exhibit 
estrogenic [34] or anti-estrogenic [35] effects, 
antimicrobial [36], spasmolytic [37] and strong 
anti-oxidative properties [38]. 
Ipriflavone, 7-isopropoxy-3-phenyl-4H-l-benzo- 
pyran-4-one (MW280.31) is an isoftavone syn- 
thesized in the late 1960s. IP is extensively 
metabolized. In rats and dogs, seven metabolites 
(MET I-VII) were found in plasma [11] but in 
humans, the main metabolites are MET I, II, III and 
V (Fig. 3). IP and MV circulate in a free form. MET 
I, II and III are extensively glycurono-conjugated. 
IP is present in plasma in very small quantities and 
the most frequent metabolites are MET I and II, in 
conjugated forms and MET V as unconjugated, 
suggesting that this latter metabolite should 
contribute greatly to the action of IP [39]. 
Our results suggest hat, at the tested doses, IP 
and its metabolites do not influence human 
chondrocyte proliferation. IP and MET I were 
shown previously to stimulate proliferation of a 
clonal cell population of rat osteoblastic ells 
(UMR-106) [5] by up to 193% of basal value. It is 
noteworthy that, in this particular trial, the 
dose-response curves for the effect of IP on cell 
proliferation showed a biphasic pattern, with a 
maximum effect at 0.1 nM IP and a decline in the 
stimulatory effect by increasing the dose of the 
compound. In the present experiment, we tested 
much higher doses of IP and its metabolites 
(1-100 gg/1 corresponding to 4-400/~M). Our results 
are thus in accordance with those observed in 
UMR-106 cells [5], when no stimulatory effects 
were observed with doses of IP and metabolites 
from 0.1 pM. In our model, PG and COL II synthesis 
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are significantly enhanced by IP (PG and COL II) 
and MET I (PG), III and V (PG and COL II). The 
PG released into" the culture media may be a 
reflection of increased metalloprotease activity, 
and not from an increase in synthesis of PG. 
However this hypothesis i probably unlikely since 
a previous report performed in the same culture 
model and at concentrations similar to those used 
in the present work showed that IP and MET I and 
III inhibited interleukin-l-stimulated collagenase 
and stromelysine synthesis [40]. A similar stimu- 
latory effect was reported previously for bio- 
synthetical properties of UMR-106 cells which 
synthesize collagen and alkaline phosphatases, 
but the authors found, once again, a biphasic 
pattern with a maximum effect in the range 
of 0.1-1 nM and an absence of stimulation with 
higher doses [5]. In our experiment, much higher 
doses (up to 100 pg/ml, corresponding to 400 pM) 
induced a substantial increase in the production 
of matrix components. Our observations are, 
however, in close accordance with other reports, 
suggesting a direct effect of IP on collagen 
synthesis and bone formation [41, 42]. In human 
clinical practice, the administration of a daily dose 
(600mg) of IP for 2 years, is reported to have 
beneficial effects on bone mass in post-menopausal 
and senile osteoporosis [1-3], inducing a plateau of 
IP and its metabolites in the circulating blood 
levels with concentrat ion i the micromolar range 
[43, 44]. Furthermore, MET V, like IP, appears 
to stimulate PG and COL II secretion in our 
model. They are recovered in unconjugated form 
in the human body [43, 44] and are thought 
to contribute greatly to the action of IP. We 
therefore believe that the effects described in vitro 
for IP and its main metabolites, at the concen- 
trations equivalent to those found in blood in vitro 
after repeated administration, may be of clinical 
significance, 
In conclusion IP and its metabolites, at doses 
from 1-100 #g/ml do not modulate cell proliferation 
in a model of three-dimensional culture of human 
chondrocytes. However, IP, MET I, III and V 
significantly increase matrix components (PG and 
COL II) suggesting that at the concentration used, 
IP and its metabolites do not appear to be toxic to 
chondrocytes in cluster. 
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